PARSIPPANY, N.J.-- (BUSINESS WIRE)--Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today that the ...

The US Food and Drug Administration (FDA) has signed off on a ready-to-use formulation of vigabatrin developed by Pryos Pharmaceuticals for infantile spasms, marking the first approval for a novel ...

Credit: Pyros Pharmaceuticals. Vigafyde is supplied as a peppermint-flavored oral solution in a 150mL bottle. Vigafyde ™, a ready-to-use oral solution formulation of vigabatrin, is now available for ...

"Parents with children who have infantile spasms are dealing with multiple issues and concerns when caring for their child. The experts at PANTHERx have been helping children and infants with ...

Founded in 2017 by Michael Smith and Edwin Urrutia, Pyros recently launched VIGAFYDE (vigabatrin) oral solution, which is indicated as monotherapy for the treatment of infantile spasms (IS) in ...

MAPLE GROVE, Minn., Dec. 2, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its participation at AES 2024, the Annual Meeting of the American Epilepsy Society, from ...

PARSIPPANY, N.J., September 03, 2024--(BUSINESS WIRE)--Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, is ...

Founded in 2017 by Michael Smith and Edwin Urrutia, Pyros recently launched VIGAFYDETM (vigabatrin) oral solution, which is indicated as monotherapy for the treatment of infantile spasms (IS) in ...

PARSIPPANY, N.J., June 17, 2024--(BUSINESS WIRE)--Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced ...